Literature DB >> 21107554

Right ventricle and tricuspid valve function at midterm after the Fontan operation for hypoplastic left heart syndrome: impact of shunt type.

Victor Bautista-Hernandez1, Mark Scheurer, Ravi Thiagarajan, Joshua Salvin, Frank A Pigula, Sitaram Emani, Francis Fynn-Thompson, Hugo Loyola, Jared Schiff, Pedro J del Nido, Emile A Bacha.   

Abstract

This study aimed to evaluate clinical outcomes including hemodynamics, right ventricle (RV) function, and tricuspid valve (TV) function in patients with hypoplastic left heart syndrome (HLHS) at midterm after completion of staged palliation based on the source of pulmonary blood flow provided at stage 1. The records of all patients with HLHS who completed Fontan palliation between 2001 and 2007 were retrospectively reviewed. The outcome variables were RV dysfunction, TV, and neo-atrioventricular (neo-AV) regurgitation (from latest echocardiogram), cardiac index (CI), pulmonary vascular resistance (PVR), pulmonary artery pressure (PAp), and right ventricular end-diastolic pressure (RVEDp) (from latest catheterization). Clinical status was obtained from medical records and by contact with the referring cardiologist if necessary. Of 118 patients undergoing a Fontan for HLHS, 116 had a fenestrated lateral tunnel and 2 had an extracardiac conduit. At the time of stage 1 palliation, 36 patients had a right ventricle-to-pulmonary artery (RV-PA) conduit, and 82 patients had a modified Blalock-Taussig shunt (mBTS). All the patients except one who died of sepsis on extracorporeal membrane oxygenation (ECMO) survived the Fontan operation and were discharged home. At a mean follow-up post-Fontan period of 28.4 months (range, 0.16-95.3 months), three patients had died (2 on the transplantation list and 1 from pulmonary vein stenosis), and one patient had the Fontan circulation taken down. No patient had a heart transplantation. A follow-up echocardiogram was performed for 115 patients (after a mean of 15.6 months for RV-PA and 32.1 months for BTS), and 66 patients underwent a post-Fontan catheterization (after a mean of 15.8 months for RV-PA and 29.3 months for BTS). The hemodynamic results for RV-PA conduit versus BTS were a CI of 3.4 ± 0.8 versus 3.4 ± 1.2, a PVR of 1.8 ± 0.7 versus 1.7 ± 0.8, a PAp of 14.3 ± 3.1 versus 14.2 ± 4.5, and an RVEDp of 7.1 ± 3.3 versus 8.9 ± 5.3. No statistically significant differences were found between shunt types regarding survival or degree of RV dysfunction or in terms of neo-AV regurgitation, CI, PVR, PAp, RVEDp, or rhythm problems. Patients in the BTS group required more tricuspid valvuloplasties and had more tricuspid regurgitation at follow-up evaluation. The patients in the RV-PA group had more PA interventions. In conclusion, the contemporary results after Fontan palliation for HLHS were excellent. At the midterm follow-up evaluation, outcomes and hemodynamic data were similar between shunt types. However, the patients in the BTS group exhibited more tricuspid regurgitation, and the patients in the RV-PA group had increased pulmonary artery interventions.

Entities:  

Mesh:

Year:  2010        PMID: 21107554     DOI: 10.1007/s00246-010-9835-1

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  21 in total

1.  Comparison of right ventricle to pulmonary artery conduit and modified Blalock-Taussig shunt hemodynamics after the Norwood operation.

Authors:  Richard G Ohye; Achiau Ludomirsky; Eric J Devaney; Edward L Bove
Journal:  Ann Thorac Surg       Date:  2004-09       Impact factor: 4.330

2.  Improved interstage mortality with the modified Norwood procedure: a meta-analysis.

Authors:  Clifford L Cua; Ravi R Thiagarajan; Roozbeh Taeed; Timothy M Hoffman; Lillian Lai; John Hayes; Peter C Laussen; Timothy F Feltes
Journal:  Ann Thorac Surg       Date:  2005-07       Impact factor: 4.330

3.  Physiologic repair of aortic atresia-hypoplastic left heart syndrome.

Authors:  W I Norwood; P Lang; D D Hansen
Journal:  N Engl J Med       Date:  1983-01-06       Impact factor: 91.245

4.  Outcomes after the stage I reconstruction comparing the right ventricular to pulmonary artery conduit with the modified Blalock Taussig shunt.

Authors:  Sarah Tabbutt; Troy E Dominguez; Chitra Ravishankar; Bradley S Marino; Peter J Gruber; Gil Wernovsky; J William Gaynor; Susan C Nicolson; Thomas L Spray
Journal:  Ann Thorac Surg       Date:  2005-11       Impact factor: 4.330

5.  Right ventricle to pulmonary artery conduit improves outcome after stage I Norwood for hypoplastic left heart syndrome.

Authors:  Christian Pizarro; Edward Malec; Kevin O Maher; Katarzyna Januszewska; Samuel S Gidding; Kenneth A Murdison; Jeanne M Baffa; William I Norwood
Journal:  Circulation       Date:  2003-09-09       Impact factor: 29.690

6.  Survival and clinical course at Fontan after stage one palliation with either a modified Blalock-Taussig shunt or a right ventricle to pulmonary artery conduit.

Authors:  Mark A Scheurer; Joshua W Salvin; Vladimiro L Vida; Francis Fynn-Thompson; Emile A Bacha; Frank A Pigula; John E Mayer; Pedro J del Nido; David L Wessel; Peter C Laussen; Ravi R Thiagarajan
Journal:  J Am Coll Cardiol       Date:  2008-07-01       Impact factor: 24.094

7.  Risk factors for mortality after the Norwood procedure using right ventricle to pulmonary artery shunt.

Authors:  Shunji Sano; Shu-Chien Huang; Shingo Kasahara; Ko Yoshizumi; Yasuhiro Kotani; Kozo Ishino
Journal:  Ann Thorac Surg       Date:  2009-01       Impact factor: 4.330

8.  Risk factors for interstage death after stage 1 reconstruction of hypoplastic left heart syndrome and variants.

Authors:  David A Hehir; Troy E Dominguez; Jean A Ballweg; Chitra Ravishankar; Bradley S Marino; Geoffrey L Bird; Susan C Nicolson; Thomas L Spray; J William Gaynor; Sarah Tabbutt
Journal:  J Thorac Cardiovasc Surg       Date:  2008-05-22       Impact factor: 5.209

9.  Right ventricle-pulmonary artery shunt in first-stage palliation of hypoplastic left heart syndrome.

Authors:  Shunji Sano; Kozo Ishino; Masaaki Kawada; Sadahiko Arai; Shingo Kasahara; Tomohiro Asai; Zen-ichi Masuda; Mamoru Takeuchi; Shin-ichi Ohtsuki
Journal:  J Thorac Cardiovasc Surg       Date:  2003-08       Impact factor: 5.209

10.  Early postoperative outcomes in a series of infants with hypoplastic left heart syndrome undergoing stage I palliation operation with either modified Blalock-Taussig shunt or right ventricle to pulmonary artery conduit.

Authors:  Clifford L Cua; Ravi R Thiagarajan; Kimberlee Gauvreau; Lillian Lai; John M Costello; David L Wessel; Pedro J Del Nido; John E Mayer; Jane W Newburger; Peter C Laussen
Journal:  Pediatr Crit Care Med       Date:  2006-05       Impact factor: 3.624

View more
  3 in total

1.  Impact of initial shunt type on cardiac size and function in children with single right ventricle anomalies before the Fontan procedure: the single ventricle reconstruction extension trial.

Authors:  Peter C Frommelt; Eric Gerstenberger; James F Cnota; Meryl S Cohen; Jessica Gorentz; Kevin D Hill; J Blaine John; Jami C Levine; Jimmy Lu; William T Mahle; Rachel T McCandless; Luc Mertens; Gail D Pearson; Carolyn Spencer; Deepika Thacker; Ismee A Williams; Pierre C Wong; Jane W Newburger
Journal:  J Am Coll Cardiol       Date:  2014-11-03       Impact factor: 24.094

2.  Does initial shunt type for the Norwood procedure affect echocardiographic measures of cardiac size and function during infancy?: the Single Vventricle Reconstruction trial.

Authors:  Peter C Frommelt; Lin T Guey; L LuAnn Minich; Majeed Bhat; Tim J Bradley; Steve D Colan; Greg Ensing; Jessica Gorentz; Haleh Heydarian; J Blaine John; Wyman W Lai; Jami C Levine; William T Mahle; Stephen G Miller; Richard G Ohye; Gail D Pearson; Girish S Shirali; Pierre C Wong; Meryl S Cohen
Journal:  Circulation       Date:  2012-04-21       Impact factor: 29.690

3.  Mechanical tricuspid valve replacement in hypoplastic left heart syndrome: An institutional experience.

Authors:  Mehar Hoda; Robert Douglas Benjamin Jaquiss; Lorraine James; Poonam Punjwani Thankavel
Journal:  JTCVS Open       Date:  2022-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.